Stock Monitor: CASI Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on Enanta Pharma, Inc. (NASDAQ: ENTA) ("Enanta"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ENTA as the Company's latest news hit the wire. On April 12, 2018, the Company announced it will present data from Enanta's wholly-owned development programs, including EP-027367, one of Enanta's novel core inhibitors in preclinical testing targeting hepatitis B virus (HBV), and EDP-305, an FXR agonist in development for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), at The International Liver Congress? (ILC) 2018, April 11-15, in Paris, France. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for CASI Pharmaceuticals, Inc. (NASDAQ: CASI), which also belongs to the Healthcare sector as the Company Enanta Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=CASI

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Enanta Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ENTA

EP-027367 Reduced Hepatitis B Virus DNA Levels in Chimeric Mouse Model with Human Liver Cells

The abstract titled: "Discovery of a novel HBV core inhibitor EP-027367 with potent antiviral activity both in vitro and in a humanized mouse model" - was presented in an oral presentation on April 12, 2018. Data that was presented demonstrated that in a chimeric mouse model with human liver cells, EP-027367 reduced hepatitis B virus DNA levels by up to 3.0 logs from baseline in HBV viral titers with 4 weeks of treatment and demonstrated a favorable tolerability and pharmacokinetic profile. EP-027367 has also demonstrated potent, pan-genotypic, anti-HBV activity capable of preventing the establishment of cccDNA in vitro.

Enanta to Present Three Posters on EDP-305

The Company also announced three posters on EDP-305. One poster will highlight new preclinical data demonstrating EDP-305 favorably regulates the expression of key fibrogenic genes in-vitro and in-vivo and a second will show EDP-305 has distinct transcriptional and post-transcriptional regulatory mechanisms for LDLR and SRB1 expression. A third poster will present data from Enanta's previously released phase-1 study highlighting the pharmacokinetics, pharmacodynamics, and safety of EDP-305 in healthy and presumptive NAFLD subjects.

Additionally, several abstracts from AbbVie will be presented on their HCV regimens containing glecaprevir/pibrentasvir and marketed under the tradenames MAVYRET? (US) and MAVIRET? (ex-US). Glecaprevir is Enanta's second protease inhibitor discovered and commercialized through its protease inhibitor collaboration with AbbVie.

About EP-027367 and EDP-305

EP-027367 is one of several core inhibitors Enanta is evaluating for HBV. Core inhibitors, sometimes referred to as capsid assembly modulators, are a new class of HBV inhibitors that can disrupt the assembly and replication of the virus at multiple steps in the virus lifecycle.

EDP-305 is a potent agonist of FXR, a nuclear receptor that is the main regulator of bile acid levels in the liver and small intestine. FXR responds to bile acids by regulating gene transcription of key enzymes and transporters, many of which play important roles in lipid metabolism, insulin resistance, inflammation, and fibrosis. The US Food and Drug Administration (FDA) has granted EDP-305 Fast Track designation for the treatment of NASH patients with liver fibrosis and Fast Track designation for the treatment of patients with PBC

About Enanta Pharmaceuticals, Inc.

Headquartered in Watertown, Massachusetts, Enanta Pharma is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. The Company's research and development is currently focused on the disease targets including HBV, NASH/PBC and Respiratory Syncytial Virus (RSV).

Stock Performance Snapshot

April 13, 2018 - At Friday's closing bell, Enanta Pharma's stock rose 1.46%, ending the trading session at $85.98.

Volume traded for the day: 89.00 thousand shares.

Stock performance in the last month ? up 1.28%; previous three-month period ? up 42.66%; past twelve-month period ? up 191.95%; and year-to-date - up 46.52%

After last Friday's close, Enanta Pharma's market cap was at $1.62 billion.

Price to Earnings (P/E) ratio was at 46.73.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors